EP
ACTU

Essential Partners’s Actuate Therapeutics ACTU Stock Holding History

Essential Partners’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256 Buy
167
+119
+248% +$276 ﹤0.01% 2599
2026
Q1 		$132 Buy
+48
New +$199 ﹤0.01% 2678

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Essential Partners's ACTU Position: Q2 2026 in Review

Essential Partners increased its Actuate Therapeutics (ACTU) stake by 248% in Q2 2026, buying an estimated $276 and bringing the position to 167 shares worth $256. The position accounts for ﹤0.01% of the portfolio, ranked #2599.

Essential Partners first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Essential Partners held 167 shares of Actuate Therapeutics worth $256 as of Q2 2026.
  • Essential Partners bought 119 Actuate Therapeutics shares in Q2 2026, an estimated $276.
  • Actuate Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2599 holding.
  • Essential Partners first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.